Laboratory / preclinical
Preclinical only
Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: hair follicle and dermal papilla biology
Also known as: Copper peptide AHK-Cu
AHK-Cu is the copper complex of the tripeptide Ala-His-Lys. A published ex vivo and in vitro study found increased elongation of cultured human hair follicles and proliferation of dermal papilla cells at picomolar-to-nanomolar concentrations. These laboratory findings do not establish a clinical hair-growth effect or a systemic administration protocol. AHK-Cu has a smaller evidence base than GHK-Cu and is commonly sold in topical cosmetic formulations and as bulk powder.
Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.
Data source: Published human hair-follicle ex vivo and dermal papilla-cell in vitro study
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.
10^-12 to 10^-9 M continuous exposure
Context: published human hair-follicle and dermal papilla-cell study PMID 17703734
Route safety: Non-human or laboratory exposure. It cannot be converted into a human dose.
10^-12 to 10^-9 M continuous exposure
Context: published human hair-follicle and dermal papilla-cell study PMID 17703734
Route safety: Non-human or laboratory exposure. It cannot be converted into a human dose.
No route-specific amount established in the reviewed record.
Context: The catalog identifies this route, but its reviewed sources do not establish a separate amount and schedule for it.
Formulation: Concentration, vehicle, treated area, and product sterility are formulation-specific.
Route safety: No route-specific protocol is established. Do not infer an amount from another route, component, or formulation.
Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.
No published evidence supports SC administration of AHK-Cu. The protocol now reflects the concentrations used in the published ex vivo and in vitro study rather than a vendor-derived topical percentage.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.